Allakos (NASDAQ:ALLK) slides 7.3% after Muddy Waters says it is short on the company, citing an undisclosed Phase 1 trial that “raises troubling concerns.”
From Muddy Waters’ tweet
about the study: “Study uses 10 mg/kg (3x Phase 2 high dose). ALLK
claims Phase 2 high dose reduced EOS 97%. Why test triple dose and risk
adverse events if true?”
The tweet includes an attached Phase 1 consent form.
https://seekingalpha.com/news/3545900-allakosminus-7-after-muddy-waters-says-short
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.